前颅底脑膜瘤中SMO与AKT1的靶向测序
该研究对62例前颅底脑膜瘤患者进行SMO与AKT1靶向测序,发现SMO突变7例(11%)、AKT1突变12例(19%),合计30%存在可临床干预的突变;SMO突变组肿瘤体积显著大于AKT1突变组和野生型组。
要点
- 前颅底脑膜瘤中SMO突变占11%(7/62),AKT1突变占19%(12/62)。
- 7例SMO突变中6例(86%)位于嗅沟。
- SMO突变组肿瘤体积70.6±36.3 cm³,大于AKT1突变组18.2±26.8 cm³和野生型组22.7±23.9 cm³。
核心结论
- 前颅底脑膜瘤中30%存在可临床干预的突变,SMO突变状态与肿瘤体积可能存在关联。
- 对具有手术组织的前颅底脑膜瘤进行SMO与AKT1基因分型可能高产。
研究设计与样本
- 对62例前颅底脑膜瘤患者的大队列进行靶向测序。
主要发现
- SMO突变见于7/62(11%),AKT1突变见于12/62(19%)。
- 7例SMO突变脑膜瘤中6例(86%)位于嗅沟。
- SMO突变组肿瘤体积70.6±36.3 cm³,分别大于AKT1突变组18.2±26.8 cm³和野生型组22.7±23.9 cm³。
临床怎么用
- 原文结论认为对具有手术组织的前颅底脑膜瘤进行SMO与AKT1基因分型可能高产。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Meningiomas located in the skull base are surgically challenging. Recent genomic research has identified oncogenic SMO and AKT1 mutations in a small subset of meningiomas. METHODS The authors performed targeted sequencing in a large cohort of patients with anterior skull base meningiomas (n = 62) to better define the frequency of SMO and AKT1 mutations in these tumors. RESULTS The authors found SMO mutations in 7 of 62 (11%) and AKT1 mutations in 12 of 62 (19%) of their cohort. Of the 7 meningiomas with SMO mutations, 6 (86%) occurred in the olfactory groove. Meningiomas with an SMO mutation presented with significantly larger tumor volume (70.6 ± 36.3 cm3) compared with AKT1-mutated (18.2 ± 26.8 cm3) and wild-type (22.7 ± 23.9 cm3) meningiomas, respectively. CONCLUSIONS Combined, these data demonstrate clinically actionable mutations in 30% of anterior skull base meningiomas and suggest an association between SMO mutation status and tumor volume. Genotyping of SMO and AKT1 is likely to be high yield in anterior skull base meningiomas with available surgical tissue.
引用
- Strickland MR, Gill CM, Nayyar N, et al. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg. 2016. PMID: 27885953. doi:10.3171/2016.8.JNS161076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。